OTC : ADIA

Adia Med Inc. — News

$0.112 USD

-$0.01 (-6.67%)

Volume
500
Average Volume
13.18K
Market Capitalization
$10.57M
P/E Ratio
-0.03
Dividend Yield
0.00%
Price Target
Year High
$0.28
Year Low
$0.03
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.11
Source Headline
Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing

Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m.

newsfilecorp.com - 2026-08-11 08:00:00

Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities

Winter Park, Florida--(Newsfile Corp. - August 5, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced that it will host a private dinner for physicians and investors on Wednesday, August 5, 2026, at 7:00 PM at Christner's Steakhouse. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/308113_adia_med_x_banner.jpg The dinner will provide an overview of Adia Med's current clinical studies, including its ongoing Autism Spectrum Disorder research study and other regenerative medicine initiatives.

newsfilecorp.com - 2026-08-05 16:30:00

Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study

Next Cohort of 30 Children to Begin a New Phase 1 Treatment Group on October 1, 2026, as Successive Enrollment Continues Every Three Months Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as part of the study's ongoing, staggered enrollment schedule.

newsfilecorp.com - 2026-07-29 06:00:00

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

New Platform Now Live, Featuring Expanded Sections on Clinical Studies, Stem Cell Therapies, Aesthetics, Media, Podcasts, Case Studies, and Investor Resources Winter Park, Florida--(Newsfile Corp. - July 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a clinical-stage regenerative medicine company, today announced the launch of its redesigned corporate website. The redesigned website is now live, with the project still in progress and active changes and improvements currently being made.

newsfilecorp.com - 2026-07-15 09:30:00

Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

Winter Park, Florida--(Newsfile Corp. - July 13, 2026) - Adia Med Inc. (OTCQB: ADIA) (formerly Adia Nutrition Inc.), focused on regenerative medicine, stem cell therapies, and biologics, today highlighted its rapid advancement and major milestones achieved since the January 2024 leadership transition. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/304722_adia_med_x_banner.jpg On January 22, 2024, Larry Powalisz assumed the role of CEO and Director following a change of control, with Rebecca Miller appointed as CFO.

newsfilecorp.com - 2026-07-13 09:00:00

Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review

Name change to appear on Daily List today following expedited review; trading begins tomorrow Winter Park, Florida--(Newsfile Corp. - July 9, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA) announced today that FINRA has processed its corporate name change to Adia Med Inc. on an expedited timeline. The name change will be reflected on the FINRA Daily List today, with trading under the new name expected to begin tomorrow, Friday, July 10, 2026, on the OTC Markets.

newsfilecorp.com - 2026-07-09 08:00:00

Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.

Company Believes All Requirements Satisfied; Approval Expected in the Coming Weeks Winter Park, Florida--(Newsfile Corp. - July 7, 2026) - Adia Nutrition Inc. (OTCQB: ADIA) today announced it has entered the final stage of its corporate name change application from Adia Nutrition Inc. to Adia Med Inc. After several months of review by the Financial Industry Regulatory Authority (FINRA), including three rounds of comments and the submission of detailed supporting documentation, the Company believes it has now met all outstanding requirements. FINRA approval is anticipated within the coming weeks.

newsfilecorp.com - 2026-07-07 10:19:00

Adia Med Finds Another Unicorn

CEO Larry Powalisz Spotlights Dr. Lyday, a Leading Stem Cell Champion, in New Podcast. Winter Park, Florida--(Newsfile Corp. - June 30, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine and stem cell therapies company, today announced that CEO Larry Powalisz recently sat down for a podcast interview with Dr. Lyday, a physician recognized as a champion for stem cell-based treatments.

newsfilecorp.com - 2026-06-30 12:49:00

Adia Med Improves Quality of Care with Advanced Ultrasound-Guided IV Training

Dr. Brian Browning to train APRNs and RNs on Butterfly portable ultrasound for more precise, comfortable, and reliable IV therapies Winter Park, Florida--(Newsfile Corp. - June 16, 2026) - Adia Med, the regenerative medicine and advanced IV therapy division of Adia Nutrition Inc. (OTCQB: ADIA), today announced a major step forward in patient care quality. Renowned physician Dr. Brian Browning, DO, Lead Physician at Adia Med, will personally train the company's Advanced Practice Registered Nurses (APRNs) and Registered Nurses (RNs) in ultrasound-guided intravenous (IV) insertions and administrations using the innovative Butterfly portable ultrasound device.

newsfilecorp.com - 2026-06-16 10:55:00

Adia Nutrition Inc. Delivers Exciting Update: Name Change to Adia Med Inc. Now Official in Nevada

Winter Park, Florida--(Newsfile Corp. - June 10, 2026) - Adia Nutrition Inc. (OTCQB: ADIA) is pleased to confirm that the State of Nevada has officially approved the company's name change to Adia Med Inc. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/300817_screenshot_adia_med_inc_official_on_nevada.jpg The move is more than cosmetic — it's a clear signal of where Adia is headed. Shifting from "Nutrition" to "Med" puts the spotlight on the company's growing emphasis on advanced medical and wellness solutions.

newsfilecorp.com - 2026-06-10 09:15:00

Adia Nutrition Launches Dynamic New Subsidiary ADIA Life LLC in Florida to Supercharge Distribution and Unlock a Full Spectrum of Life-Transforming Wellness Solutions

Winter Park, Florida--(Newsfile Corp. - June 8, 2026) - Adia Nutrition (OTCQB: ADIA), a leader in advanced nutrition and regenerative health products, today announced the official launch of its new wholly-owned subsidiary, ADIA Life LLC, headquartered in the state of Florida. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/300531_screenshot_adia_life_llc_registration.jpg ADIA Life LLC was strategically created to serve as the central hub for managing distribution of Adia Labs' cutting-edge products while also overseeing a growing network of authorized distributors nationwide.

newsfilecorp.com - 2026-06-08 12:51:00

Adia Nutrition, Inc. Drops Explosive Sneak Peek of Upcoming Documentary Featuring TNA Wrestling Star Jeff Sciullo (Elias)

Winter Park, Florida--(Newsfile Corp. - June 2, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA) is thrilled to announce that the powerful new documentary showcasing TNA Wrestling star and former WWE superstar Jeff Sciullo, known to fans worldwide as Elias (or Elijah), is in final editing and racing toward release! Wrestler's Tricep Tears Off Bone During Match!

newsfilecorp.com - 2026-06-02 09:30:00

Adia Nutrition Announces Expanded Stem Cell Coverage Through Independent Monthly-Membership Health Care Sharing Ministry

Winter Park, Florida--(Newsfile Corp. - May 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine and innovative healthcare solutions, today announced that an independent monthly-membership health care sharing ministry — where members pay monthly dues as an alternative to traditional health insurance — now accepts up to three stem cell treatments per client. This expanded coverage provides eligible members with greater access to advanced stem cell therapies for regenerative applications.

newsfilecorp.com - 2026-05-26 08:00:00

Adia Med Now Recruiting for Kidney Health and Lower Back Pain Studies Listed on ClinicalTrials.gov

Winter Park, Florida--(Newsfile Corp. - May 20, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine, today announced that its subsidiary Adia Med of Winter Park LLC is now actively recruiting participants for two key clinical studies officially listed as "Recruiting" on ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07572890#study-overview To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/298208_kidneystudy.jpg Each study is enrolling up to 100 participants.

newsfilecorp.com - 2026-05-20 11:57:50

ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026

Winter Park, Florida--(Newsfile Corp. - May 15, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced nutrition and regenerative health solutions, today announced its 3rd party reviewed financial results for the first quarter ended March 31, 2026, highlighting significant year-over-year revenue growth and continued expansion of its biologics and medical procedures segments. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001160420/000168316826003957/adia_i10q-033126.htm To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/297620_adia_image1.jpg Key Highlights for Q1 2026 (compared to Q1 2025): Total Revenue increased 146% to $176,275 from $71,764, reflecting strong demand and successful diversification of revenue streams.

newsfilecorp.com - 2026-05-15 07:59:00

ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov

Winter Park Autism Study Now Treating Patients; Kidney Study Recruitment to Begin This Week Winter Park, Florida--(Newsfile Corp. - May 11, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine through its subsidiary Adia Med of Winter Park, LLC, today announced that all four of its planned clinical studies have received Institutional Review Board (IRB) approval. This milestone enables the continued execution and launch of human trials evaluating the safety and potential efficacy of the Company's proprietary AdiaVita™ stem cell and exosome therapies.

newsfilecorp.com - 2026-05-11 10:04:00

Get ADIA Insider Trade Alerts

ADIA Price Target Summary

Last Month

0 analysts

Last Quarter

0 analysts

Last Year

0 analysts

All Time

0 analysts

ADIA Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade